Develops molecular diagnostic tests for infectious diseases and other conditions.
Talis Biomedical Corporation is a pioneering molecular diagnostic company at the forefront of advancing healthcare through innovative testing solutions. Central to its mission is the development of the Talis One system, designed to overcome the limitations of current point-of-care diagnostic technologies, particularly for infectious diseases. This cutting-edge platform represents a significant leap forward in rapid and accurate testing capabilities, aiming to enhance patient care and disease management.
Founded in 2013 and based in Menlo Park, California, Talis Biomedical Corporation is dedicated to tackling urgent healthcare challenges with its groundbreaking technologies. The company's flagship product, the Talis One COVID-19 Test System, is specifically engineered for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond COVID-19, Talis Biomedical is expanding its portfolio to include the Talis One assay kit, catering to a spectrum of respiratory infections, women's health issues, and sexually transmitted infections. Additionally, the company offers specialized tests such as a respiratory panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus.
Talis Biomedical Corporation serves as a pivotal player in the molecular diagnostics landscape, collaborating closely with healthcare providers, laboratories, and public health entities. By pushing the boundaries of diagnostic innovation, Talis Biomedical continues to empower clinicians and researchers with advanced tools that deliver timely and accurate diagnostic insights, ultimately aiming to improve patient outcomes worldwide.